Gyre Therapeutics (GYRE) announced that the first volunteer has been successfully dosed in a Phase 1 clinical trial evaluating F230, a novel endothelin A receptor antagonist, for the treatment of pulmonary arterial hypertension. F230, originally discovered by Eisai (ESAIY) and exclusively licensed by GNI Group Ltd. to Gyre, is a fully synthetic small molecule designed to selectively block the ETA receptor. By targeting this pathway, F230 is designed to reduce pulmonary vascular remodeling and lower pulmonary pressure, key contributors to PAH progression.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GYRE:
- Gyre Therapeutics Holds 2025 Annual Stockholders Meeting
- Gyre Therapeutics Announces Stock Offering Agreement
- Stocks slide as Trump threatens new tariffs against EU and Apple: Morning Buzz
- Catalyst Biosciences Inc trading resumes
- Catalyst Biosciences Inc trading halted, volatility trading pause